INVESTIGATION OF THE MECHANISM OF TAMOXIFEN-STIMULATED BREAST-TUMOR GROWTH WITH NONISOMERIZABLE ANALOGS OF TAMOXIFEN AND METABOLITES

Citation
Dm. Wolf et al., INVESTIGATION OF THE MECHANISM OF TAMOXIFEN-STIMULATED BREAST-TUMOR GROWTH WITH NONISOMERIZABLE ANALOGS OF TAMOXIFEN AND METABOLITES, Journal of the National Cancer Institute, 85(10), 1993, pp. 806-812
Citations number
46
Categorie Soggetti
Oncology
Volume
85
Issue
10
Year of publication
1993
Pages
806 - 812
Database
ISI
SICI code
Abstract
Background: The nonsteroidal antiestrogen tamoxifen (TAM) is the front -line endocrine treatment for breast cancer, but disease recurrence is common. Treatment failure may occur because tumors become insensitive to TAM. Alternatively, resistance may occur because tumors become sti mulated rather than inhibited by TAM. TAM-stimulated growth of MCF-7 h uman breast tumors has been observed in athymic mice after prolonged t reatment with TAM. Purpose: Our purpose was to examine the mechanism o f treatment failure by determining whether TAM-stimulated tumors acqui re the ability to excrete TAM and its antiestrogenic metabolites or to convert them to estrogenic compounds with weakened antiestrogenic act ivity. Methods: We used high-pressure liquid chromatography to quantit ate TAM and its metabolites in serum and tumors from ovariectomized at hymic mice and in MCF-7 cells grown in vitro. We treated tumor-bearing mice with subcutaneous sustained-release preparations of estradiol, T AM, or a nonisomerizable (fixed-ring) analogue and then assessed the a ctivity of these compounds on TAM-inhibited parental MCF-7 tumors and on TAM-stimulated MCF-7 TAM tumors. Results: We found negligible diffe rences in intratumoral TAM levels between TAM-inhibited parental MCF-7 tumors and TAM-stimulated MCF-7 TAM variants. We did not detect metab olite E (Met E), an estrogenic TAM metabolite, in serum or tumors. Usi ng MCF-7 cells in vitro, we determined that the (Z) isomer of Met E, t he form directly produced by TAM metabolism, must be present in the ce ll at a concentration of over 1000 ng/g to overcome growth inhibition by physiological levels of TAM and antiestrogenic metabolites, but the (E) isomer of Met E was effective at 10 ng/g. We reasoned that conver sion of Met E from the (Z) (a weak estrogen) to (E) isomer (a potent e strogen) would be required if formation of Met E were responsible for TAM-stimulated growth. However, fixed-ring TAM, which can only form (Z ) Met E, was shown to be as capable as TAM of initiating and maintaini ng antiestrogen-stimulated growth of MCF-7 tumors in athymic mice. Con clusion: Metabolism and isomerization of TAM to estrogenic compounds i s not the mechanism of TAM-stimulated growth in our model. Implication : Other potential mechanisms for TAM-stimulated growth, such as estrog en receptor mutation, must be investigated so that effective strategie s can be devised to control breast cancer once therapy fails.